Bristol pulls ahead of Amgen
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
Revolution mortgages royalties for more cash
“We need all the capital we can get our hands on," the company states.
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
“We need all the capital we can get our hands on," the company states.
